Meta-Analysis of Genomic and Transcriptomic Variations in Lung Adenocarcinoma

Background Lung cancer is the leading cause of the largest number of deaths worldwide and lung adenocarcinoma is the most common form of lung cancer. In order to understand the molecular basis of lung adenocarcinoma, integrative analysis have been performed by using genomics, transcriptomics, epigenomics, proteomics and clinical data. Besides, molecular prognostic signatures have been generated for lung adenocarcinoma by using gene expression levels in tumor samples. However, we need signatures including different types of molecular data, even cohort or patient-based biomarkers which are the candidates of molecular targeting. Results We built an R pipeline to carry out an integrated meta-analysis of the genomic alterations including single-nucleotide variations and the copy number variations, transcriptomics variations through RNA-seq and clinical data of patients with lung adenocarcinoma in The Cancer Genome Atlas project. We integrated significant genes including single-nucleotide variations or the copy number variations, differentially expressed genes and those in active subnetworks to construct a prognosis signature. Cox proportional hazards model with Lasso penalty and LOOCV was used to identify best gene signature among different gene categories. We determined a 12-gene signature (BCHE, CCNA1, CYP24A1, DEPTOR, MASP2, MGLL, MYO1A, PODXL2, RAPGEF3, SGK2, TNNI2, ZBTB16) for prognostic risk prediction based on overall survival time of the patients with lung adenocarcinoma. The patients in both training and test data were clustered into high-risk and low-risk groups by using risk scores of the patients calculated based on selected gene signature. The overall survival probability of these risk groups was highly significantly different for both training and test datasets. Conclusions This 12-gene signature could predict the prognostic risk of the patients with lung adenocarcinoma in TCGA and they are potential predictors for the survival-based risk clustering of the patients with lung adenocarcinoma. These genes can be used to cluster patients based on molecular nature and the best candidates of drugs for the patient clusters can be proposed. These genes also have a high potential for targeted cancer therapy of patients with lung adenocarcinoma.

[1]  H. Tian,et al.  Twenty-gene-based prognostic model predicts lung adenocarcinoma survival , 2018, OncoTargets and therapy.

[2]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[3]  J. Witte,et al.  Podocalyxin variants and risk of prostate cancer and tumor aggressiveness. , 2006, Human molecular genetics.

[4]  Li Jin,et al.  Hypermethylation reduces expression of tumor‐suppressor PLZF and regulates proliferation and apoptosis in non‐small‐cell lung cancers , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  Kathleen Marchal,et al.  SomInaClust: detection of cancer genes based on somatic mutation patterns of inactivation and clustering , 2015, BMC Bioinformatics.

[6]  G. Casey,et al.  Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin. , 2007, Cancer research.

[7]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[8]  Trevor Hastie,et al.  Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent. , 2011, Journal of statistical software.

[9]  W. Gerald,et al.  A Genome-Wide Screen for Promoter Methylation in Lung Cancer Identifies Novel Methylation Markers for Multiple Malignancies , 2006, PLoS medicine.

[10]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[11]  Davis J. McCarthy,et al.  Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation , 2012, Nucleic acids research.

[12]  T. Dragani,et al.  Cigarette smoke alters the transcriptome of non-involved lung tissue in lung adenocarcinoma patients , 2019, Scientific Reports.

[13]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[14]  V. Afshar-Kharghan.  The role of the complement system in cancer , 2017, The Journal of clinical investigation.

[15]  Ru-kun He,et al.  A Robust 8-Gene Prognostic Signature for Early-Stage Non-small Cell Lung Cancer , 2019, Front. Oncol..

[16]  Angela N. Brooks,et al.  High-throughput Phenotyping of Lung Cancer Somatic Mutations. , 2016, Cancer cell.

[17]  Yi Shi,et al.  Cardiac troponin I is abnormally expressed in non-small cell lung cancer tissues and human cancer cells. , 2014, International journal of clinical and experimental pathology.

[18]  S. Landas,et al.  Monoglyceride lipase gene knockout in mice leads to increased incidence of lung adenocarcinoma , 2018, Cell Death & Disease.

[19]  D. Arango,et al.  Brush border myosin Ia inactivation in gastric but not endometrial tumors , 2013, International journal of cancer.

[20]  Dean E Brenner,et al.  CYP24A1 Is an Independent Prognostic Marker of Survival in Patients with Lung Adenocarcinoma , 2010, Clinical Cancer Research.

[21]  Shicheng Li,et al.  Identification of an eight-gene prognostic signature for lung adenocarcinoma , 2018, Cancer management and research.

[22]  Hui Jiang,et al.  Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma , 2017, Journal of the National Cancer Institute.

[23]  Yassen Assenov,et al.  Maftools: efficient and comprehensive analysis of somatic variants in cancer , 2018, Genome research.

[24]  X. Hua,et al.  Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study , 2016, PLoS medicine.

[25]  H. Nielsen,et al.  Serum Mannan-Binding Lectin-Associated Serine Protease 2 Levels in Colorectal Cancer: Relation to Recurrence and Mortality , 2005, Clinical Cancer Research.

[26]  Athanasios K. Tsakalidis,et al.  DEsubs: an R package for flexible identification of differentially expressed subpathways using RNA-seq experiments , 2016, Bioinform..

[27]  W. Travis.  Pathology of lung cancer. , 2002, Clinics in chest medicine.

[28]  W. Jiao,et al.  Associations between abnormal vitamin D metabolism pathway function and non-small cell lung cancer. , 2017, Oncology letters.

[29]  D. Huntsman,et al.  Overexpression of the Anti-Adhesin Podocalyxin Is an Independent Predictor of Breast Cancer Progression , 2004, Cancer Research.

[30]  P. Visca,et al.  Determination of SGK1 mRNA in non-small cell lung cancer samples underlines high expression in squamous cell carcinomas , 2012, Journal of experimental & clinical cancer research : CR.

[31]  Jianjin Xu,et al.  Cognitive function in multiple sclerosis improves with telerehabilitation: Results from a randomized controlled trial , 2017, PloS one.

[32]  Wenzhi Liu,et al.  Epac1 is involved in cell cycle progression in lung cancer through PKC and Cx43 regulation. , 2015, Folia histochemica et cytobiologica.

[33]  P. Unger,et al.  Down-regulation of cytoplasmic PLZF correlates with high tumor grade and tumor aggression in non-small cell lung carcinoma. , 2015, Human pathology.

[34]  T. Lumley,et al.  Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker , 2000, Biometrics.

[35]  A. Rivera,et al.  Cyclin A1 is a p53-induced gene that mediates apoptosis, G2/ M arrest, and mitotic catastrophe in renal, ovarian, and lung carcinoma cells , 2006, Cellular and Molecular Life Sciences CMLS.

[36]  Mingming Jia,et al.  COSMIC: somatic cancer genetics at high-resolution , 2016, Nucleic Acids Res..

[37]  Guang-Cong Zhang,et al.  SGK2 promotes hepatocellular carcinoma progression and mediates GSK-3β/β-catenin signaling in HCC cells , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[38]  Ying Liang,et al.  An expression signature model to predict lung adenocarcinoma-specific survival , 2018, Cancer management and research.

[39]  M. Kloor,et al.  Brush border Myosin Ia has tumor suppressor activity in the intestine , 2012, Proceedings of the National Academy of Sciences.

[40]  D.,et al.  Regression Models and Life-Tables , 2022 .

[41]  Yunqian Hu,et al.  Pathogenic mechanisms of lung adenocarcinoma in smokers and non-smokers determined by gene expression interrogation. , 2015, Oncology letters.

[42]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[43]  Phase stability and electronic structure of iridium metal at the megabar range , 2019, Scientific Reports.

[44]  Ki Lui,et al.  Potential Tumor Suppressive Role of Monoglyceride Lipase in Human Colorectal Cancer , 2012, Oncogene.

[45]  D. Nomura,et al.  Monoacylglycerol Lipase Regulates a Fatty Acid Network that Promotes Cancer Pathogenesis , 2010, Cell.

[46]  J. Yokota,et al.  MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1. , 2014, Cancer discovery.

[47]  Seon-Young Kim,et al.  Integrative analysis for the discovery of lung cancer serological markers and validation by MRM-MS , 2017, PloS one.

[48]  P. Grambsch,et al.  A Package for Survival Analysis in S , 1994 .

[49]  Zhao min Deng,et al.  Analysis of genomic variation in lung adenocarcinoma patients revealed the critical role of PI3K complex , 2017, PeerJ.

[50]  Hemant Ishwaran,et al.  Evaluating Random Forests for Survival Analysis using Prediction Error Curves. , 2012, Journal of statistical software.

[51]  Xiaodong Cheng,et al.  Exchange protein directly activated by cAMP encoded by the mammalian rapgef3 gene: Structure, function and therapeutics , 2015, Gene.

[52]  Shuanying Yang,et al.  Five genes may predict metastasis in non-small cell lung cancer using bioinformatics analysis , 2019, Oncology letters.

[53]  San-Gang Wu,et al.  21-Gene Recurrence Score Assay and Outcomes of Adjuvant Radiotherapy in Elderly Women With Early-Stage Breast Cancer After Breast-Conserving Surgery , 2019, Front. Oncol..

[54]  E. Birney,et al.  Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt , 2009, Nature Protocols.

[55]  S. Eschrich,et al.  Transforming growth factor β-induced epithelial-to-mesenchymal signature predicts metastasis-free survival in non-small cell lung cancer , 2019, Oncotarget.

[56]  H. Nielsen,et al.  Increased activity of the mannan‐binding lectin complement activation pathway in patients with colorectal cancer , 2004, Scandinavian journal of gastroenterology.

[57]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[58]  S. Cho,et al.  Induction of cell apoptosis in non‐small cell lung cancer cells by cyclin A1 small interfering RNA , 2006, Cancer science.

[59]  Gianluca Bontempi,et al.  TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data , 2015, Nucleic acids research.

[60]  Jiing-Dwan Lee,et al.  BMK1 kinase suppresses epithelial-mesenchymal transition through the Akt/GSK3β signaling pathway. , 2012, Cancer research.

[61]  F. Ruíz-Espejo,et al.  Cholinesterase activity of human lung tumours varies according to their histological classification. , 2006, Carcinogenesis.

[62]  D. Beer,et al.  Oncogenic Potential of CYP24A1 in Lung Adenocarcinoma , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[63]  Michele Ceccarelli,et al.  Finding recurrent copy number alterations preserving within-sample homogeneity , 2011, Bioinform..

[64]  Hua Zhu,et al.  Reciprocal Negative Regulation between EGFR and DEPTOR Plays an Important Role in the Progression of Lung Adenocarcinoma , 2016, Molecular Cancer Research.

[65]  Zoltan Szallasi,et al.  A robust prognostic gene expression signature for early stage lung adenocarcinoma , 2016, Biomarker Research.

[66]  Mingwei Chen,et al.  Gene polymorphism of cytochrome P450 significantly affects lung cancer susceptibility , 2019, Cancer medicine.